Status:
COMPLETED
Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-s...
Eligibility Criteria
Inclusion
- ≥18，Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients received platinum-based chemotherapy combined with immunotherapy
Exclusion
- EGFR/ALK/ROS1 driver gene mutation
- Chemotherapy only
- Concurrent radio-chemotherapy
- Surgery
- Single-agent immunotherapy
- No treatment information available
Key Trial Info
Start Date :
January 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 2 2022
Estimated Enrollment :
636 Patients enrolled
Trial Details
Trial ID
NCT05205226
Start Date
January 2 2018
End Date
January 2 2022
Last Update
January 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013